Kristin Burns
Primary Care · Kent, WANPI 1609401686
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 24 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by AbbVie at 40.1% of the total. Reporting peaked in 2023 at $249 and has fallen 69.4% since, to $76 in 2024.
Across 24 payments — averaging $20.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$196
- Novo Nordisk$134
- Astellas Pharma US Inc$52
- Mayne Pharma Commercial LLC$41
- Boehringer Ingelheim$28
- AstraZeneca$25
- plus $13 from 1 others
What the payments were for
- Food & beverage$488100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 8 | $196 |
| Novo Nordisk | 4 | $134 |
| Astellas Pharma US Inc | 2 | $52 |
| Mayne Pharma Commercial LLC | 7 | $41 |
| Boehringer Ingelheim | 1 | $28 |
| AstraZeneca | 1 | $25 |
| Agile Therapeutics, Inc. | 1 | $13 |
How this compares
$488 in reported general payments places this provider in the 65th percentile of 94 primary care providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Duloxetine Hcl | 12 | $677 |
| Metformin Hcl ErMetformin Hcl | 59 | $596 |
| Gabapentin | 25 | $378 |
| Atorvastatin Calcium | 57 | $351 |
| Naproxen | 12 | $328 |
| Lisinopril | 47 | $288 |
| Amlodipine Besylate | 34 | $211 |
| Quetiapine Fumarate | 12 | $207 |
| Trazodone Hcl | 12 | $195 |
| Omeprazole | 17 | $193 |
| Losartan Potassium | 23 | $188 |
| Levothyroxine Sodium | 13 | $151 |
| Hydrochlorothiazide | 13 | $146 |
| Clonazepam | 11 | $132 |
| Rosuvastatin Calcium | 12 | $121 |
Paid to pharmacies, not to this prescriber.
Other primary care in Kent
- Abubakar Abdul-RahmanSeattle$27K
- Junghee CheLakewood$20K
- Margaret StewartMill Creek$14K
- Rhonna LeeSpokane$13K
- Joan ZimmerSpokane$12K
- Kimberly RianoOlympia$8K
- James PittmanSpokane$6K
- Shannon ZawilskiPuyallup$4K
- Laura RaykowskiMontesano$3K
- Sara AppudorayPuyallup$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.